Mónica Renuncio-García

Ms. Mónica Renuncio-García


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2022 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
DPDiana Prieto-Peña
Diana Prieto-Peña
J. Gonzalo Ocejo-VinyalsJ. Gonzalo Ocejo-Vinyals
J. Gonzalo Ocejo-Vinyals
JMJoel Mazariegos-Cano
Joel Mazariegos-Cano
APAna L. Pelayo-Negro
Ana L. Pelayo-Negro
SRSara Remuzgo-Martínez
Sara Remuzgo-Martínez
José Luis HernándezJosé Luis Hernández
José Luis Hernández

25 April 2024 in Human Immunology
Verified
Journal Article
Closed access
ACAlejandra Comins-Boo
Alejandra Comins-Boo
JIJuan Irure-Ventura
Juan Irure-Ventura
MVMaria O Valentin
Maria O Valentin
LBLara Belmar-Vega
Lara Belmar-Vega
CCCovadonga López Del Moral Cuesta
Covadonga López Del Moral Cuesta
DSDavid San Segundo
David San Segundo

1 November 2022 in Transplantation Proceedings
Verified
Journal Article
Closed access
MRMónica Renuncio-García
Mónica Renuncio-García
EGElena González-López
Elena González-López
ECEnric Carreras
Enric Carreras
JVJuliana Villa
Juliana Villa
IRIñigo Romón-Alonso
Iñigo Romón-Alonso
DSDavid San Segundo
David San Segundo

22 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IFIván Ferraz-Amaro
Iván Ferraz-Amaro
ZIZeina Ibrahim-Achi
Zeina Ibrahim-Achi
AVAntonia de Vera-González
Antonia de Vera-González
ADAlejandra González Delgado
Alejandra González Delgado
MRMónica Renuncio-García
Mónica Renuncio-García
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
Background: Soluble cell adhesion molecules such as sICAM-1 (soluble intercellular adhesion molecule-1), sVCAM-1 (soluble vascular cell adhesion molecule-1), and P-selectin have been implicated in cardiovascular disease pathogenesis in the general population. Cardiovascular disease is prevalent among patients with systemic sclerosis (SSc). This study aims to investigate potential associations between the serum levels of these adhesion molecules and specific cardiovascular comorbidities in SSc patients. Methods: This cross-sectional study encompassed 81 individuals with SSc. All SSc patients underwent a complete clinical evaluation. Serum sICAM-1, sVCAM-1, and P-selectin levels, lipid profiles and insulin resistance indices, and carotid ultrasound were assessed. Multivariable linear regression analyses were employed to investigate potential associations between adhesion molecule levels (sICAM, sVCAM, and P-selectin) and both SSc-specific manifestations and cardiometabolic parameters. Results: The associations of disease-related parameters with sICAM-1, sVCAM-1, and P-selectin levels were limited. Notably, only the modified Rodnan skin score exhibited a significant positive association with sVCAM-1 levels, while no such associations were observed for sICAM-1 and P-selectin. Regarding cardiovascular disease-related data, sVCAM-1 significantly correlated with higher values of insulin resistance and beta-cell function indices. In the case of P-selectin, although a trend was observed, statistical significance was not reached. Conclusions: In patients with SSc, serum values of sVCAM-1 independently correlate with insulin resistance. The assessment of CAMs in patients with SSc could serve as a valuable clinical tool for identifying individuals with increased insulin resistance and a higher risk of cardiovascular disease.

17 November 2025 in Rheumatology
Verified
Journal Article
Closed access
IFIván Ferraz-Amaro
Iván Ferraz-Amaro
MHMarta Hernández-Díaz
Marta Hernández-Díaz
JGJosé Carlos García-Hernández
José Carlos García-Hernández
AVAna Isabel Rodríguez Vargas
Ana Isabel Rodríguez Vargas
MRMónica Renuncio-García
Mónica Renuncio-García
FDFederico Diaz-Gonzalez
Federico Diaz-Gonzalez
Objectives: The effects of systemic tumour necrosis factor (TNF) inhibition on glucose homeostasis are not fully understood. This study aims to evaluate the effects of TNF inhibitors (TNFis) on gastric inhibitory polypeptide (GIP), amylin and pancreatic polypeptide (PP), hormones involved in the fine-tuning of postprandial glucose homeostasis, in patients with RA, PsA and axial spondylarthritis (axSpA). Methods: Sixty-four non-diabetic patients (RA, n = 22; PsA, n = 13; axSpA, n = 29) undergoing TNFi therapy were prospectively evaluated at baseline and after 12, 24 and 52 weeks. Assessments included measurements of disease activity, acute-phase reactants, fasting glucose, insulin and C-peptide levels, insulin resistance as assessed by the updated Homeostatic Model Assessment (HOMA)2 and lipid profile. Serum concentrations of amylin, GIP and PP were measured at each visit. Multivariable linear mixed-effects models were used to analyse temporal changes in clinical and biochemical variables. Results: Basal insulin resistance indices did not significantly change throughout the study in patients with RA, PsA or axSpA. However, serum basal levels of GIP, amylin and PP significantly increased in the univariable model, and the results remained consistent after adjusting for CRP, at 12, 24 and 52 weeks of TNFi therapy. These effects were consistent and specific across different TNFi types and diagnoses, except for PP, which exhibited a significant interaction with the type of arthritis. Conclusions: In patients initiating TNFi therapy, serum levels of GIP, amylin and PP increase regardless of systemic inflammation. This effect on postprandial glucose-regulating hormones may help explain the cardiovascular benefits of TNFi in rheumatic inflammatory diseases, at least in part.

6 June 2025 in Sci
Verified
Journal Article
Open access
PDF file
MLMaría del Amparo Sánchez López
María del Amparo Sánchez López
CLCarmen Lasa-Teja
Carmen Lasa-Teja
MRMónica Renuncio-García
Mónica Renuncio-García
CACristina Abraira-Meriel
Cristina Abraira-Meriel
SSSaray Simón-Coloret
Saray Simón-Coloret
RBRicardo Blanco
Ricardo Blanco
Cryofibrinogenemia (CF) may be secondary to COVID-19. To establish this relationship, in PRECOVID-19 and COVID-19 periods we assess: (a) frequency and clinical features in patients with CF; (b) study of CF syndrome. We study all cryofibrinogen tests performed in a single university hospital in Northern Spain, comparing two periods: PRECOVID-19 (July 2017–February 2020) and COVID-19 (March 2020–October 2022). CF syndrome was established with two positive cryofibrinogen tests plus compatible cutaneous manifestations and/or thrombotic events (TE). CF was found in 129/279 patients. In the COVID-19 period, they had more positive tests (50.2% vs. 28%; p = 0.0047), younger age (33 vs. 55 years, p = 0.054) and fewer cardiovascular (CV) risk factors (39.1% vs. 78.6%, p = 0.005). Cutaneous manifestations were the most frequent in both periods (81.4%), particularly purpuric macules (29.5%). Skin ulcers showed statistically significant differences, being more frequent in the PRECOVID-19 era (35.7% vs. 7.8%, p = 0.008). Thrombotic CV events were also observed (13.2%), particularly venous thromboembolisms (12.2%). Severe complications were more frequent in the PRECOVID-19 era, although this difference did not reach statistical significance (35.7% vs. 19.1%; p = 0.169). CF was secondary in 68/129 cases, mainly to SARS-CoV-2 (n = 45). CF syndrome was found in 27.9% of patients. After one year, most patients were clinically stable or in remission. Mild dermatological lesions were the most frequent manifestations, and most patients recovered.